New ultrasound technique may spot breast cancer treatment success early
NCT ID NCT05957042
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study aimed to see if contrast-enhanced ultrasound (CEUS) could predict how well triple-negative breast cancer patients respond to chemotherapy and immunotherapy. Researchers planned to measure tumor volume and blood flow changes with CEUS before and during treatment. However, the study was withdrawn before any patients were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lumason (contrast agent)
What this could lead to
If successful, this could provide a faster, non-invasive way to see if breast cancer treatment is working, potentially guiding therapy changes earlier.
What could go wrong
This is a very early pilot study that was withdrawn before enrolling any participants, so no data exists. The approach may not prove reliable compared to standard imaging.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Penn State Health College of Medicine
Hershey, Pennsylvania, 17033, United States